ZHEJIANG TIANYU PHARMACEUTICAL CO.,LTD

Company Introduction for Zhejiang Tianyu Pharmaceutical Co., Ltd. (Singapore)

Zhejiang Tianyu Pharmaceutical Co., Ltd. is a prominent pharmaceutical enterprise with its primary manufacturing operations located in Taizhou, Zhejiang Province, China. The company is a large-scale manufacturer specializing in the research, development, production, and sales of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates. Their product portfolio primarily serves cardiovascular, antiviral, and endocrine therapeutic fields, among others.

In Singapore, Zhejiang Tianyu Pharmaceutical Co., Ltd. functions as a trading and sales arm. This Singapore-based entity serves as a regional office responsible for international business development, sales, marketing, and distribution of the parent company's manufactured products. It facilitates global trade and strengthens the company's presence in the Asia-Pacific market, providing a hub for logistics and customer relations.

Business Type: Trader (for its Singapore operations). The parent company in China is a manufacturer/factory.

Zhejiang Tianyu Pharmaceutical Co., Ltd. is a pharmaceutical company based in Zhejiang, China. They primarily specialize in the research, development, production, and sales of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates.

Their main product categories and specific products include:

Cardiovascular System Drugs (APIs and Intermediates):

- Valsartan and its intermediates

- Irbesartan and its intermediates

- Olmesartan and its intermediates

- Candesartan Cilexetil and its intermediates

- Losartan Potassium and its intermediates

- Telmisartan and its intermediates

Antidiabetic Drugs (Intermediates):

- Sitagliptin intermediates

Anticoagulants (Intermediates):

- Apixaban intermediates

Antiviral Drugs (Intermediates):

- Favipiravir intermediates

While Zhejiang Tianyu Pharmaceutical Co., Ltd. is based in China, as a global supplier of APIs and intermediates, their products are sold to pharmaceutical manufacturers worldwide, including potentially to companies in Singapore, who then use these raw materials to produce finished drug products for various markets.